Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis?

Youxue Wang, Satoru Naruse, Motoji Kitagawa, Hiroshi Ishiguro, Yasuyuki Nakae, Toshiyuki Yoshikawa, Tetsuo Hayakawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Plasma and urine levels of trypsinogen activation peptides (TAP) reflect the severity of acute pancreatitis in experimental and clinical acute pancreatitis. In trypsin-taurocholate-induced pancreatitis in rats, the extrinsic bovine trypsin used for the induction of pancreatitis might influence on the TAP levels after induction of pancreatitis. The aim of the present study was to elucidate whether infused trypsin itself affects TAP levels in trypsin-taurocholate-induced pancreatitis. Rats were divided into three groups. In the pancreatitis group, acute pancreatitis was induced by a retrograde infusion of bovine trypsin and sodium taurocholate into the pancreatic duct. In the duct infusion group and peritoneal injection group, a mixture of bovine trypsin and trypsin inhibitor, ONO-3403, was infused into the pancreatic duct or the peritoneal cavity. Plasma and urine TAP concentration significantly increased in trypsin-taurocholate-induced pancreatitis but not in the duct infusion and peritoneal injection groups for 6 hours after the infusion of trypsin. Serum rat immunoreactive trypsin (IRT) and amylase significantly increased in the pancreatitis and duct infusion groups but not in the peritoneal injection group. Serum levels of bovine IRT in the pancreatitis group was significantly lower than those in duct infusion and peritoneal injection groups. In conclusion, an intraductal infusion of bovine trypsin itself into pancreatic duct does not influence the levels of plasma and urine TAP in trypsin-taurocholate-induced pancreatitis.

Original languageEnglish (US)
Pages (from-to)389-393
Number of pages5
JournalPancreas
Volume20
Issue number4
DOIs
StatePublished - May 2000

Fingerprint

trypsinogen activation peptide
Taurocholic Acid
Pancreatitis
Trypsin
Urine
Parenteral Infusions
Pancreatic Ducts
Injections

Keywords

  • Acute pancreatitis
  • Trypsin
  • Trypsinogen activation peptides (TAP)

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Cite this

Wang, Y., Naruse, S., Kitagawa, M., Ishiguro, H., Nakae, Y., Yoshikawa, T., & Hayakawa, T. (2000). Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis? Pancreas, 20(4), 389-393. https://doi.org/10.1097/00006676-200005000-00009

Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis? / Wang, Youxue; Naruse, Satoru; Kitagawa, Motoji; Ishiguro, Hiroshi; Nakae, Yasuyuki; Yoshikawa, Toshiyuki; Hayakawa, Tetsuo.

In: Pancreas, Vol. 20, No. 4, 05.2000, p. 389-393.

Research output: Contribution to journalArticle

Wang, Y, Naruse, S, Kitagawa, M, Ishiguro, H, Nakae, Y, Yoshikawa, T & Hayakawa, T 2000, 'Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis?', Pancreas, vol. 20, no. 4, pp. 389-393. https://doi.org/10.1097/00006676-200005000-00009
Wang, Youxue ; Naruse, Satoru ; Kitagawa, Motoji ; Ishiguro, Hiroshi ; Nakae, Yasuyuki ; Yoshikawa, Toshiyuki ; Hayakawa, Tetsuo. / Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis?. In: Pancreas. 2000 ; Vol. 20, No. 4. pp. 389-393.
@article{71d8b0f6e3bd4a428ee60be4e7467a02,
title = "Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis?",
abstract = "Plasma and urine levels of trypsinogen activation peptides (TAP) reflect the severity of acute pancreatitis in experimental and clinical acute pancreatitis. In trypsin-taurocholate-induced pancreatitis in rats, the extrinsic bovine trypsin used for the induction of pancreatitis might influence on the TAP levels after induction of pancreatitis. The aim of the present study was to elucidate whether infused trypsin itself affects TAP levels in trypsin-taurocholate-induced pancreatitis. Rats were divided into three groups. In the pancreatitis group, acute pancreatitis was induced by a retrograde infusion of bovine trypsin and sodium taurocholate into the pancreatic duct. In the duct infusion group and peritoneal injection group, a mixture of bovine trypsin and trypsin inhibitor, ONO-3403, was infused into the pancreatic duct or the peritoneal cavity. Plasma and urine TAP concentration significantly increased in trypsin-taurocholate-induced pancreatitis but not in the duct infusion and peritoneal injection groups for 6 hours after the infusion of trypsin. Serum rat immunoreactive trypsin (IRT) and amylase significantly increased in the pancreatitis and duct infusion groups but not in the peritoneal injection group. Serum levels of bovine IRT in the pancreatitis group was significantly lower than those in duct infusion and peritoneal injection groups. In conclusion, an intraductal infusion of bovine trypsin itself into pancreatic duct does not influence the levels of plasma and urine TAP in trypsin-taurocholate-induced pancreatitis.",
keywords = "Acute pancreatitis, Trypsin, Trypsinogen activation peptides (TAP)",
author = "Youxue Wang and Satoru Naruse and Motoji Kitagawa and Hiroshi Ishiguro and Yasuyuki Nakae and Toshiyuki Yoshikawa and Tetsuo Hayakawa",
year = "2000",
month = "5",
doi = "10.1097/00006676-200005000-00009",
language = "English (US)",
volume = "20",
pages = "389--393",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Do plasma and urine trypsinogen activation peptides (TAP) really increase in trypsin-taurocholate-induced pancreatitis?

AU - Wang, Youxue

AU - Naruse, Satoru

AU - Kitagawa, Motoji

AU - Ishiguro, Hiroshi

AU - Nakae, Yasuyuki

AU - Yoshikawa, Toshiyuki

AU - Hayakawa, Tetsuo

PY - 2000/5

Y1 - 2000/5

N2 - Plasma and urine levels of trypsinogen activation peptides (TAP) reflect the severity of acute pancreatitis in experimental and clinical acute pancreatitis. In trypsin-taurocholate-induced pancreatitis in rats, the extrinsic bovine trypsin used for the induction of pancreatitis might influence on the TAP levels after induction of pancreatitis. The aim of the present study was to elucidate whether infused trypsin itself affects TAP levels in trypsin-taurocholate-induced pancreatitis. Rats were divided into three groups. In the pancreatitis group, acute pancreatitis was induced by a retrograde infusion of bovine trypsin and sodium taurocholate into the pancreatic duct. In the duct infusion group and peritoneal injection group, a mixture of bovine trypsin and trypsin inhibitor, ONO-3403, was infused into the pancreatic duct or the peritoneal cavity. Plasma and urine TAP concentration significantly increased in trypsin-taurocholate-induced pancreatitis but not in the duct infusion and peritoneal injection groups for 6 hours after the infusion of trypsin. Serum rat immunoreactive trypsin (IRT) and amylase significantly increased in the pancreatitis and duct infusion groups but not in the peritoneal injection group. Serum levels of bovine IRT in the pancreatitis group was significantly lower than those in duct infusion and peritoneal injection groups. In conclusion, an intraductal infusion of bovine trypsin itself into pancreatic duct does not influence the levels of plasma and urine TAP in trypsin-taurocholate-induced pancreatitis.

AB - Plasma and urine levels of trypsinogen activation peptides (TAP) reflect the severity of acute pancreatitis in experimental and clinical acute pancreatitis. In trypsin-taurocholate-induced pancreatitis in rats, the extrinsic bovine trypsin used for the induction of pancreatitis might influence on the TAP levels after induction of pancreatitis. The aim of the present study was to elucidate whether infused trypsin itself affects TAP levels in trypsin-taurocholate-induced pancreatitis. Rats were divided into three groups. In the pancreatitis group, acute pancreatitis was induced by a retrograde infusion of bovine trypsin and sodium taurocholate into the pancreatic duct. In the duct infusion group and peritoneal injection group, a mixture of bovine trypsin and trypsin inhibitor, ONO-3403, was infused into the pancreatic duct or the peritoneal cavity. Plasma and urine TAP concentration significantly increased in trypsin-taurocholate-induced pancreatitis but not in the duct infusion and peritoneal injection groups for 6 hours after the infusion of trypsin. Serum rat immunoreactive trypsin (IRT) and amylase significantly increased in the pancreatitis and duct infusion groups but not in the peritoneal injection group. Serum levels of bovine IRT in the pancreatitis group was significantly lower than those in duct infusion and peritoneal injection groups. In conclusion, an intraductal infusion of bovine trypsin itself into pancreatic duct does not influence the levels of plasma and urine TAP in trypsin-taurocholate-induced pancreatitis.

KW - Acute pancreatitis

KW - Trypsin

KW - Trypsinogen activation peptides (TAP)

UR - http://www.scopus.com/inward/record.url?scp=0034057461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034057461&partnerID=8YFLogxK

U2 - 10.1097/00006676-200005000-00009

DO - 10.1097/00006676-200005000-00009

M3 - Article

C2 - 10824694

AN - SCOPUS:0034057461

VL - 20

SP - 389

EP - 393

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 4

ER -